Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| (NASDAQ: VIR) | Delayed: 10.57 +0.14 (1.34%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.43 | 52 Week High | $ | |||
| Open | $10.36 | 52 Week Low | $ | |||
| Day High | $10.59 | P/E | N/A | |||
| Day Low | $10.03 | EPS | $ | |||
| Volume | 1,693,540 | |||||
